PRA Health Sciences Inc

PRA Health Sciences — Q4 2015 Earnings Presentation

17 slides from PRA Health Sciences's earnings presentation, Feb 24, 2016

  1. Slide 1: Forward Looking Statements and Use of Non-GAAP Financial Measures

    Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements that reflect, among other things, the Company’s current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and o

  2. Slide 2: Q4 2015 Highlights

    Q4 2015 Highlights ($ in millions) $362.3 million of service revenue; 15.1% constant currency growth $67.9 million of Adjusted EBITDA; 34.2% growth compared to prior year Adjusted Net Income per share of $0.59; 68.6% growth compared to prior year Q4 2015 Q4 2014 % Change Service Revenue $362.3 $323.

  3. Slide 3: Trailing Quarterly Performance

    Trailing Quarterly Performance Adjusted Income from Operations ($M) Adjusted EBITDA Margin (%) Service Revenue ($M) Adjusted EBITDA ($M) $33.7 $40.6 $41.0 $45.2 $50.6 $56.2 $61.2 $62.4 Q1 2014 Q2 2014 Q3 2014 Q4 2014 Q1 2015 Q2 2015 Q3 2015 Q4 2015 12.7% 14.6% 14.7% 15.6% 16.8% 18.2% 19.3% 18.8% 11%

  4. Slide 4: Backlog and New Business Awards

    Backlog and New Business Awards Ending Backlog ($M) Backlog Conversion % Net Book-to-Bill Net New Business Awards ($M) 1.13 1.19 1.19 1.20 1.20 1.21 1.25 1.27 Q1 2014 Q2 2014 Q3 2014 Q4 2014 Q1 2015 Q2 2015 Q3 2015 Q4 2015 $351.3 $371.9 $382.1 $388.4 $398.0 $407.8 $431.4 $459.4 Q1 2014 Q2 2014 Q3 20

  5. Slide 5: Debt Structure

    Debt Structure Weighted Average ($ in millions) December 31, March 31, June 30, September 30, December 31, Interest Maturity 2014 2015 2015 2015 2015 Rate Date Senior debt: First Lien 729.0 $ 714.0 $ 699.0 $ 689.0 $ 689.0 $ 4.50% September 23, 2020 Senior Notes 225.0 225.0 225.0 225.0 225.0 9.50% Oc

  6. Slide 6: 2016 Guidance

    2016 Guidance Low End of Range High End of Range Service Revenue, in Millions $1,530.0 $1,570.0 Diluted GAAP Earnings per Share $1.56 $1.66 Diluted Adjusted Net Income per Share $2.32 $2.42 Annual Effective Income Tax Rate 28% 28%

  7. Slide 7: 2016 Guidance

    3 | 2016 Guidance Hea Of High End of Range Service Revenue, in Millions $1,530.0 $1,570.0 Diluted GAAP Earnings per Share $1.56 $1.66 Diluted Adjusted Net Income per Share $2.32 $2.42 Annual Effective Income Tax Rate 28% 28% PRAHEA SCIENCES 2124/2016

  8. Slide 8: Q4 and FY 2015 Financial Results

    Q4 and FY 2015 Financial Results ($ in millions) 2015 2014 % Change 2015 2014 % Change Service Revenue 362.3 $ 323.8 $ 11.9% 1,375.8 $ 1,266.6 $ 8.6% EBITDA 69.6 $ 17.4 $ 300.0% 251.5 $ 134.6 $ 86.8% Adjusted EBITDA 67.9 $ 50.6 $ 34.2% 251.6 $ 182.8 $ 37.6% Adjusted EBITDA Margin 18.8% 15.6% 18.3% 1

  9. Slide 9: Trailing Quarterly Performance

    Trailing Quarterly Performance FY 15 v ($ in millions) FY 14 % Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Change Service revenue 311.4 $ 311.3 $ 320.1 $ 323.8 $ 1,266.6 $ 332.0 $ 336.5 $ 345.1 $ 362.3 $ 1,375.8 $ 8.6% % growth Y-o-Y 87.0% 73.4% 70.2% 8.4% 52.1% 6.6% 8.1% 7.8% 11.9% 8.6% % growth Y-o-Y (constant

  10. Slide 10: Backlog and New Business Awards

    Backlog and New Business Awards FY 15 v ($ in millions) FY 14 % Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Change Beginning Backlog 1,939.7 $ 1,987.3 $ 2,044.8 $ 2,091.5 $ 1,939.7 $ 2,141.1 $ 2,185.3 $ 2,262.4 $ 2,348.4 $ 2,141.1 $ Ending Backlog 1,987.3 $ 2,044.8 $ 2,091.5 $ 2,141.1 $ 2,141.1 $ 2,185.3 $ 2,262.

  11. Slide 11: Reconciliation of GAAP EBITDA to Adjusted EBITDA

    Reconciliation of GAAP EBITDA to Adjusted EBITDA For further information regarding the reconciliation of non-GAAP measures to their corresponding GAAP equivalent please see our press release ($ in millions) 2015 2014 2015 2014 Net income (loss) 28.5 $ (22.8) $ 81.8 $ (35.7) $ Depreciation and amorti

  12. Slide 12: Reconciliation of GAAP Net Income (Loss) to Adjusted Net Income

    Reconciliation of GAAP Net Income (Loss) to Adjusted Net Income For further information regarding the reconciliation of non-GAAP measures to their corresponding GAAP equivalent please see our press release ($ in millions, except per share data) 2015 2014 2015 2014 Net income (loss) 28.5 $ (22.8) $ 8

  13. Slide 13: Reconciliation of GAAP Income from Operations to Adjusted Income from Operations

    Reconciliation of GAAP Income from Operations to Adjusted Income from Operations For further information regarding the reconciliation of non-GAAP measures to their corresponding GAAP equivalent please see our press release ($ in millions) 2015 2014 2015 2014 Income from operations 43.9 $ 11.7 $ 164.

  14. Slide 14: Geographic Breakdown

    Geographic Breakdown Region YTD 2015 YTD 2014 US/Canada 833.1 755.5 Europe/Africa 413.4 402.7 Latin America 56.6 54.0 Asia/Pacific 72.7 54.4 Grand Total 1,375.8 1,266.6 Region Q4 15 Q4 14 US/Canada $ 217.3 $ 193.4 Europe/Africa 109.2 102.9 Latin America 15.3 13.4 Asia/Pacific 20.6 14.1 Grand Total $

  15. Slide 15: Days Sales Outstanding

    Days Sales Outstanding ($ in millions) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Accounts Receivable, net 246.0 $ 241.9 $ 236.1 $ 233.3 $ 239.6 $ 281.4 $ 281.9 $ 288.3 $ Unbilled Services 102.3 98.0 113.2 105.5 132.8 115.2 118.5 126.8 Total Accounts Receivable and Unbilled Services 348.3 339.9 349.3 338.8 372.4 396.6

  16. Slide 16: Days Sales Outstanding

    | Days Sales Outstanding (Sin mitons) 2018 2015 a on cry cy a cy 3 cy ‘Accounts Receivable, net $ 2460 $ 2419 $ 2361 $ 2333 $ 2396 $ 2814 $ 2819 $ 2883 Unbilled Services 1023 980 113.2 __105.5 1328 15.2 8S 1268 Total Accounts Receivable and Unbilled Services 383-3399 39.3388 34 3966 = 400.4 AIS. ‘Ad

  17. Slide 17: PRA Health Sciences

    m\/A Ws PRAHEALTHSCIENCES HE FU RE OF CLINICAL DEVELOPME

PRA Health Sciences — Q4 2015 Earnings Presentation on 6ix